_11zon.jpg?width=380&width=600&undefined)
08 January 2026Publication
EC plans AI in vitro medical device rule changes
The EC has published a proposal that may result in (IV)MD no longer being subject to AIA HRAIS requirements.
The medical device industry is under constant pressure to innovate and yet remain price competitive. Protecting, defending and enforcing intellectual property, securing collaboration partners, obtaining market access and managing public procurement, advertising products and hedging producers against product liability issues, are just some of the challenges that we help our clients overcome.
With more and more products falling in scope of the EU Medical Device Regulation (MDR), our team provides practical advice on the full product lifecycle, from R&D and classification to marketing claims and inspections. Our lawyers are well versed with the technical requirements applying to digital health solutions, e-health, m-health and other software-driven innovations. Of note, as many of our clients develop diagnostic solutions and IVD medical devices, our team helps them navigate the new standards imposed by the EU IVD Medical Device Regulation (IVDR) ahead of the May 2022 deadline.
Local experts within the firm are actively involved with medical device trade bodies (such as the ABHI in the UK, beMedTech in Belgium, SNITEM in France, e.V.r in Germany, and MedTech Europe), so are ideally placed to assist with new challenges as they arise.
Our international team supports clients to guide them through local requirements relating to medical devices and IVDs. They also prepare them for new regulatory changes, some of which will have a significant impact on the medical device industry over the next few years, such as the MDR and IVDR applicable from May 2020 and May 2022 respectively.
Advising a multi-national medical device manufacturer to re-assess its supply chain flows for medical devices in view of the regulatory changes brought by the EU MDR. We reviewed key supply chain arrangements – and related regulatory requirements – within the group and with external suppliers across the US, Europe and Asia and preparing various agreements for the supply of components, manufacture of products, distribution, importation and export.
A US listed medical devices company on the launch of digital health products and services in the dental sector across European jurisdictions. We advised on contractual, compliance, regulatory and market access aspects of the project launch in Belgium, France, Germany, Italy, Netherlands, Norway, Spain and the UK, including in relation to the client’s customers and healthcare practices.
Advising a multinational engineering and R&D firm on the launch of its first medical device software in the EU. We supported on MDR regulatory compliance, preparation them for the new economic operators’ obligations in a digital supply chain, and product liability and criminal risks.
If you have any questions, contact a member of the Medical Devices team for assistance:
_11zon.jpg?width=380&width=600&undefined)
08 January 2026Publication
The EC has published a proposal that may result in (IV)MD no longer being subject to AIA HRAIS requirements.

18 December 2025 Publication
2026 will see several important legislative reforms and new initiatives that are expected to shape the sector’s operations and strategic priorities.
.jpg?width=380&width=380&format=webply&auto=webp)
18 December 2025 Publication
The new Directive (EU) 2024/2853 strengthens injured parties’ protection and redefines liability, burden of proof, and evidence rules in the supply chain.

23 June 2025 Publication
The EU Commission under Regulation (EU) 2022/1031, initiated its 1st investigation on 24 April 24 into China’s public procurement practices for medical devices

08 May 2025 Publication
CJEU Rules That Medical Devices with Reversible Molecular Interactions Are Medicinal Products